Table 3.

Gaps in transitioning research to clinical care

Science alone is insufficient. Gaps to be addressed in transitioning research to clinical care for T1D prevention
Challenges applicable to screening and monitoring both relatives and the general population. Efforts in relatives can inform work in the general population
• Routine clinical laboratory processes for assays validated to predict risk
• Linking screening with follow-up monitoring and social/emotional support within clinical practice
• Education about risk: clinicians, insurers, health systems, families, screened individuals
• Determine the “optimal” ages, frequency, and methods for screening and monitoring for disease progression for children and adults
• Address costs
Challenges applicable to any immune therapy approved for T1D prevention
• Endocrinologists trained in use of immune therapy or use of expert centers, referrals to nonendocrinology colleagues
• Education about risks/benefits of therapy: individuals at risk, primary care clinicians, insurers
• Address costs